The combination of drug carrier and anti-VEGFR2 monoclonal antibody can locate the drug in liver cancer cells, improve the anti-tumor effect of the drug on liver cancer cells, and reduce the side effects of epirubicin [8]. The gene discussed is KDR; the disease is neoplasm.